Ambrx Biopharma Inc (DELISTED) (AMAM:DL)
27.99
+0.01
(+0.04%)
USD |
NASDAQ |
Mar 06, 16:00
28.00
+0.01
(+0.04%)
After-Hours: 20:00
Ambrx Biopharma Research and Development Expense (TTM): 48.51M for Sept. 30, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | 48.51M |
| June 30, 2023 | 44.68M |
| Date | Value |
|---|---|
| March 31, 2023 | 48.35M |
| December 31, 2022 | 53.31M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
44.68M
Minimum
Jun 2023
53.31M
Maximum
Dec 2022
48.71M
Average
48.43M
Median
Research and Development Expense (TTM) Benchmarks
| Johnson & Johnson | 15.30B |
| Axonics Inc | 37.89M |
| Harpoon Therapeutics Inc (DELISTED) | 58.63M |
| Merck & Co Inc | 30.25B |
| RayzeBio inc (DELISTED) | -- |